FGFR1 and neoplasm: FGFR1 amplification induced a strong FGFR1 dependency that could be exploited therapeutically, and in vivo studies have demonstrated inhibition of the FGFR1 pathway with FGFR inhibitors that led to significant tumor shrinkage [13, 25], and translational clinical trials are undertaken [26].